Gemini has taken a $100 million bitcoin infusion, sending its stock price up 25% and giving the crypto exchange a fresh capital cushion. The move comes as the company reported a sharp improvement in its financials — revenue climbed 42% year-over-year to $50.3 million, while its net loss shrank 27% from $149.3 million a year earlier.
The $100 million bitcoin move
The infusion arrives as bitcoin itself trades near recent highs, though Gemini didn't disclose the counterparty behind the injection. The stock's 25% pop suggests investors see the capital as a vote of confidence — or at least a buffer against further volatility in a market that's punished crypto lenders and exchanges over the past year.
Revenue climbs, losses shrink
Gemini's top-line growth to $50.3 million marks a strong recovery from the prior year, when trading volumes slumped and regulatory scrutiny intensified. The net loss narrowing by over a quarter — from $149.3 million to roughly $109 million — shows cost-cutting and higher fee income are starting to pay off. But the company remains unprofitable, and the bitcoin infusion may be needed to cover ongoing operating expenses and compliance costs.
What the numbers say about the market
The improvement in Gemini's revenue and loss position tracks a broader rebound in crypto trading activity this year. Retail and institutional volumes have picked up, and the exchange has been adding new products to capture the flow. Still, the $100 million bitcoin infusion is a reminder that even healthy-looking balance sheets in crypto can benefit from a cash — or in this case, crypto — lifeline.
Gemini hasn't said how it plans to use the bitcoin. It could be held as a reserve asset, deployed into new lending products, or simply parked on the balance sheet as a signal to regulators and customers. Either way, the infusion gives the exchange more room to maneuver heading into the second half of 2026.
